Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter ...

CytomX Therapeutics, Inc. is downgraded to Hold ahead of key CX-2051 Phase 1 expansion data in 1Q26. Learn more about CTMX ...

Medical leaders reflect on 2025’s breakthroughs in AI, early detection, preventive care, and wellness—and explain how these shifts will shape healthcare priorities in 2026.

RejuvaCare FootRenew reports 1,900+ customer reviews as Triple Method heat-massage-compression devices gain market share ...

Health system IT departments keep their employees happy by providing mission-driven environments focused on innovation, executives told Becker’s. In fact, 13 health systems were named among the 100 ...

GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight. But they need to be taken for years, ...

As part of conversations between AI healthcare leaders on the podcast AI Amplified this year, a clear picture emerged of where artificial intelligence is genuinely transforming healthcare — and where ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

The adoption of the FAIR model was pivotal in transforming our cybersecurity strategy into a measurable, business-aligned ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.